<?xml version="1.0" encoding="UTF-8"?>
<p>Granulocyte-monocyte colony stimulating factor (GM-CSF) is another immunomodulatory cytokine reported to be present at increased levels in COVID-19 patients [
 <xref rid="B84-ijms-21-05559" ref-type="bibr">84</xref>]. In one clinical trial, adding a single dose of mAb targeting GM-CSF (mavrilimumab) to standard hospital treatment improved clinical outcomes in patients with COVID-19 [
 <xref rid="B211-ijms-21-05559" ref-type="bibr">211</xref>].
</p>
